All News
PAH diagnosis and management in the context of CTD ILD
Pulmonary arterial hypertension (PAH) is a serious complication of connective tissue disorders. Approximately 25% of patients with PAH have an underlying CTD, making CTD-PAH the second most common cause of PAH. During the session on Management of Lung Complications in CTD at APLAR 2025, Prof. Dinesh Khanna and Masataka Kuwana provided an excellent overview of PAH diagnosis and management strategies the context of CTD-ILD.
Read Article
Addressing Disparities and Unequal Burdens in ILD
Interstitial lung diseases (ILDs) represent a complex spectrum of conditions that share one unifying truth: they are almost always serious, progressive, and life-altering. But for many patients, the burden of disease does not fall evenly. We are increasingly learning that where you live, who you are, and the resources available to you, can strongly influence how ILD develops and worsens. Understanding these disparities is not about pointing fingers. Rather, it is about uncovering opportunities to deliver better, fairer care.
Read Article
SPRING-SIR Italian registry of systemic sclerosis: 1917 SSc pts, 56% had GI Sx, assoc w/ longer Dz duration, more severe Dz, diffuse SSc, ILD, digital ulcers, telangiectasias, & tobacco. In 211 very early SSc, 41% GI Sxs (most esophageal), w/ puffy fingers, & dyspnea. https://t.co/l2hStwavuu
Dr. John Cush RheumNow ( View Tweet)
Where are we now—and where are we going in ILD treatment?
📅 September 9 (TONIGHT!)| ⏰ 7PM EST (LIVE)
Rheumatology leaders Drs. Sindhu Johnson, Dr. Anna-Maria Hoffmann-Vold, Dr. Scott Matson, and Dr. Jack Cush will review the latest ACR & EULAR guidelines on interstitial lung https://t.co/E30AirP5WX
Dr. John Cush RheumNow ( View Tweet)
Obstructive sleep apnea in USA is expected to rise from 34·3% in 2020 to 46·2%, resulting in 76·6 million OSA cases by 2050. By 2050 there will be more males w/ OSA (~46 milliion) than females (30·4 million), but greater growth in females over the next 30 years. https://t.co/6YZvSusTWf
Dr. John Cush RheumNow ( View Tweet)
Multimorbidity predicts flares in rheumatoid arthritis
A study from Olmstead county and the Mayo Clinic shows that multimorbidity and social factors predict higher rheumatoid arthritis (RA) flares and lower remission rates.
https://t.co/yGrvDttcEq https://t.co/45LMtvsFor
Dr. John Cush RheumNow ( View Tweet)
September to Remember (9.5.2025)
Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD.
https://t.co/dPdweMaJuN https://t.co/aExU5kV26Q
Dr. John Cush RheumNow ( View Tweet)
Based on a survey in Japan, resolution of dry mouth was the most important symptom resolution reported by SJD pts.
The JCR CPG for SjD suggests RTX for glandular involvement while BEL for extra-glandular involvements.
#APLAR25 @RheumNow https://t.co/SsUvQIM9Eu
Links:
sheila RHEUMarampa ( View Tweet)
📍Smoking, obesity and low Vit D are significant risk factors for Pre-RA.
📍Subdoligranulum arthritogenic strain is a newly described infectious agent implicated in the pathogenesis of pre-RA
@RheumNow #ACR25 @rheumarhyme https://t.co/ZzZZlfdKmk
sheila RHEUMarampa ( View Tweet)
🌐 ILD Treatment Guidelines – LIVE Webinar
📅 Sept 9 (TOMORROW!) | ⏰ 7PM EST
An expert panel reviews ACR & EULAR guidance and looks ahead at emerging therapies.
Speakers: Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator
https://t.co/iQj8OstJDU https://t.co/WsN5vntKhH
Dr. John Cush RheumNow ( View Tweet)
SSc-ILD ABs & LESSONS:
30% of won't progress.
Triple negatives (ATA, ACA, ARA) wont progress.
Males & diffuse dz > predictive than Abs.
Great read on if Abs are biomarkers to predict Rx effect. https://t.co/YcZt4aAvL0 https://t.co/wOknKRfRHf
Dr. John Cush RheumNow ( View Tweet)
ACR Concerns on the Scientific Integrity at the CDC
On behalf of the American College of Rheumatology (ACR), we express deep concern over recent developments at the Centers for Disease Control and Prevention (CDC) that appear to undermine the agency’s longstanding commitment to https://t.co/P2J7eZN07W
Dr. John Cush RheumNow ( View Tweet)
Study of 607 systemic sclerosis (SSc) pts finds Pulm arterial HTN (PAH) in 77 (12.7%). While early immunosuppression didnt reduce odds of PAH (OR 0.74, p=0.495), early mycophenolate was protective(OR 0.12; p=0.048). Only HCQ use signif. improved survival (HR 0.04; p= 0.004). https://t.co/DbsJVZ16Zd
Dr. John Cush RheumNow ( View Tweet)
Elevated serum levels of interleukin-18 discriminate Still's disease from other autoinflammatory conditions. Sera from 53 mSAID, 220 guSAID, 49 controls show IL-18 signif increased in Still's Dz; free IL-18 levels were selectively higher in Still's disease. https://t.co/8IWXWZmWgE
Dr. John Cush RheumNow ( View Tweet)
🌐 ILD Treatment Guidelines – LIVE Webinar
📅 Sept 9 | ⏰ 7PM EST
An expert panel reviews ACR & EULAR guidance and looks ahead at emerging therapies.
Speakers: Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator
https://t.co/2F3sOjqHtr
#ILD https://t.co/KaVL1pUdCh
Dr. John Cush RheumNow ( View Tweet)
Anti-MDA5 DM is assoc w/ rapidly progr ILD & mortality risk. 26 MD5+ DM pts (age 56.6 yrs; 7/26 male) Sxs: Gottrón’s (81%), ILD (73%), periungual erythema (69%), heliotrope (61%), V-sign (42%), arthritis (42%), weakness (38%), mechanic’s (35%), Raynaud’s (19%). 7/19 RP-ILD died https://t.co/WFwavo32rB
Dr. John Cush RheumNow ( View Tweet)
Crepitus Does Not Predict Earlier/Worse OA
Young adults who experience grinding or clicking sounds in their knees post-surgery may be alarmed, but new research from La Trobe University suggests these sounds may not signal early-onset osteoarthritis.
https://t.co/bu8dgzcqdv https://t.co/CnSjv6cor9
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Be Careful What You Look For
Dr. Bryant England, University of Nebraska, presents this QD Clinic, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/avxw86CGqu https://t.co/5SH3p05Rlf
Links:
Dr. John Cush RheumNow ( View Tweet)
Turkish study of Childhood-onset arthritis (n 1713; age 6.8 yrs). Most Dx: JIA 50% (most oligo), FMF 16% (recurrent oligo), vasculitis 14% (most IgA vasculitis; 94% oligo), reactive arthritis 9% (monarthritis) & acute rheumatic fever 5% (polyarticular& migratory), SLE 5% (oligo https://t.co/HkiPT0hsr7
Dr. John Cush RheumNow ( View Tweet)
Long term outcomes of secukinumab in Children & Adolescents w/ Psoriasis (n=84). 80% completed 4 yrs of Rx w/ either low dose [N 31] & high dose [N 36]) with sustained PASI 75/90/100 results at week 208 [SEC LD: 96%/89%/52%; SEC HD: 88%/82%/73%]. No deaths; No dose-dependent https://t.co/y059SJTxP1
Dr. John Cush RheumNow ( View Tweet)
